Recent advances in chronic granulomatous disease

Journal of Infection

Volumn 69, Issue S1, 2014, Pages S32-S35

  Goldblatt, David ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Gene therapy; Haematopoietic stem cell transplant; Immunocompromise; Primary immunodeficiency

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; INFLIXIMAB; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RETROVIRUS VECTOR; SALAZOSULFAPYRIDINE; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; BURKHOLDERIA INFECTION; CANDIDIASIS; CHRONIC GRANULOMATOUS DISEASE; COLITIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ENGRAFTMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNE DEFICIENCY; INFECTIOUS COMPLICATION; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; LIVER ABSCESS; NITROBLUE TETRAZOLIUM TEST; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHAGOCYTOSIS; RECURRENT INFECTION; REDUCED INTENSITY CONDITIONING; RESPIRATORY BURST; STAPHYLOCOCCUS INFECTION; STEM CELL GENE THERAPY; TREATMENT DURATION; GENE THERAPY; GRANULOMATOUS DISEASE, CHRONIC;

GENETIC THERAPY; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 84909583919     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2014.07.013     Document Type: Article

References (38)

1. van den Berg J.M., van Koppen E., Ahlin A., Belohradsky B.H., Bernatowska E., Corbeel L., et al. Chronic granulomatous disease: the European experience. PLoS One 2009, 4(4):e5234.
2. Jones L.B., McGrogan P., Flood T.J., Gennery A.R., Morton L., Thrasher A., et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol 2008, 152(2):211-218.
3. Segal A.W. The NADPH oxidase and chronic granulomatous disease. Mol Med Today 1996, 2(3):129-135.
4. Abo A., Pick E., Hall A., Totty N., Teahan C.G., Segal A.W. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 1991, 353(6345):668-670.
5. Knaus U.G., Heyworth P.G., Evans T., Curnutte J.T., Bokoch G.M. Regulation of phagocyte oxygen radical production by the GTP-binding protein Rac 2. Science 1991, 254(5037):1512-1515.
6. Meischl C., Roos D. The molecular basis of chronic granulomatous disease. Springer Semin Immunopathol 1998, 19(4):417-434.
7. Segal B.H., Leto T.L., Gallin J.I., Malech H.L., Holland S.M. Genetic, biochemical and clinical features of chronic granulomatous disease. Medicine 2000, 79:170-200.
8. Nauseef W.M. How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev 2007, 219:88-102.
9. Ahluwalia J., Tinker A., Clapp L.H., Duchen M.R., Abramov A.Y., Pope S., et al. The large-conductance Ca2+-activated K+ channel is essential for innate immunity. Nature 2004, 427:853-858.
10. Brinkmann V., Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 2007, 5(8):577-582.
11. Bianchi M., Niemiec M.J., Siler U., Urban C.F., Reichenbach J. Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent. J Allergy Clin Immunol 2011, 127(5). 1243-52 e7.
12. Winkelstein J.A., Marino M.C., Johnston R.B., Boyle J., Curnutte J., Gallin J.I., et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000, 79(3):155-169.
13. Cale C.M., Jones A.M., Goldblatt D. Follow up of patients with chronic granulomatous disease diagnosed since 1990. Clin Exp Immunol 2000, 120(2):351-355.
14. Rosenzweig S.D. Inflammatory manifestations in chronic granulomatous disease (CGD). J Clin Immunol 2008, 28(Suppl. 1):S67-S72.
15. Bylund J., MacDonald K.L., Brown K.L., Mydel P., Collins L.V., Hancock R.E., et al. Enhanced inflammatory responses of chronic granulomatous disease leukocytes involve ROS-independent activation of NF-kappa B. Eur J Immunol 2007, 37(4):1087-1096.
16. Rieber N., Hector A., Kuijpers T., Roos D., Hartl D. Current concepts of hyperinflammation in chronic granulomatous disease. Clin Dev Immunol 2012, 2012:252460.
17. Levinsky R.J., Harvey B.A., Rodeck C.H., Soothill J.F. Phorbol myristate acetate stimulated NBT test: a simple method suitable for antenatal diagnosis of chronic granulomatous disease. Clin Exp Immunol 1983, 54(2):595-598.
18. Roesler J., Hecht M., Freihorst J., Lohmann-Matthes M.L., Emmendorffer A. Diagnosis of chronic granulomatous disease and of its mode of inheritance by dihydrorhodamine 123 and flow microcytofluorometry. Eur J Pediatr 1991, 150(3):161-165.
19. Ang E.Y., Soh J.Y., Liew W.K., Chan K.W., Thoon K.C., Chong C.Y., et al. Reliability of acute illness dihydrorhodamine-123 testing for chronic granulomatous disease. Clin Lab 2013, 59(1-2):203-206.
20. Roos D., de Boer M. Molecular diagnosis of chronic granulomatous disease. Clin Exp Immunol 2014, 175(2):139-149.
21. Ben-Ari J., Wolach O., Gavrieli R., Wolach B. Infections associated with chronic granulomatous disease: linking genetics to phenotypic expression. Expert Rev Anti Infect Ther 2012, 10(8):881-894.
22. Liese J.G., Jendrossek V., Jansson A., Petropoulou T., Kloos S., Belohradsky B.H., et al. Chronic granulomatous disease in adults. Lancet 1996, 347:220-223.
23. Marciano B.E., Rosenzweig S.D., Kleiner D.E., Anderson V.L., Darnell D.N., Anaya-O'Brien S., et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 2004, 114(2):462-468.
24. Schappi M.G., Smith V.V., Goldblatt D., Lindley K.J., Milla P.J. Colitis in chronic granulomatous disease. Arch Dis Child 2001, 84(2):147-151.
25. Levine S., Smith V.V., Malone M., Sebire N.J. Histopathological features of chronic granulomatous disease (CGD) in childhood. Histopathology 2005, 47(5):508-516.
26. Jaggi P., Scherzer R., Knieper R., Mousa H., Prasad V. Utility of screening for chronic granulomatous disease in patients with inflammatory bowel disease. J Clin Immunol 2012, 32(1):78-81.
27. Agarwal S., Mayer L. Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2013, 11(9):1050-1063.
28. Holland S.M. Chronic granulomatous disease. Clin Rev Allergy Immunol 2010, 38(1):3-10.
29. Uzel G., Orange J.S., Poliak N., Marciano B.E., Heller T., Holland S.M. Complications of tumor necrosis factor-alpha blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 2010, 51(12):1429-1434.
30. Seger R.A. Hematopoietic stem cell transplantation for chronic granulomatous disease. Immunol Allergy Clin N Am 2010, 30(2):195-208.
31. Gungor T., Teira P., Slatter M., Stussi G., Stepensky P., Moshous D., et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 2014, 383(9915):436-448.
32. Cole T., Pearce M.S., Cant A.J., Cale C.M., Goldblatt D., Gennery A.R. Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. J Allergy Clin Immunol 2013, 132(5):1150-1155.
33. Cole T., McKendrick F., Titman P., Cant A.J., Pearce M.S., Cale C.M., et al. Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant. J Clin Immunol 2013, 33(1):8-13.
34. Malech H.L., Maples P.B., Whiting-Theobald N., Linton G.F., Sekhsaria S., Vowells S.J., et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 1997, 94(22):12133-12138.
35. Grez M., Reichenbach J., Schwable J., Seger R., Dinauer M.C., Thrasher A.J. Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther 2011, 19(1):28-35.
36. Kang H.J., Bartholomae C.C., Paruzynski A., Arens A., Kim S., Yu S.S., et al. Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial. Mol Ther 2011, 19(11):2092-2101.
37. Stein S., Ott M.G., Schultze-Strasser S., Jauch A., Burwinkel B., Kinner A., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010, 16(2):198-204.
38. Santilli G., Almarza E., Brendel C., Choi U., Beilin C., Blundell M.P., et al. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther 2011, 19(1):122-132.